Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enflicoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 8/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5856546 | 0.91 | PTGS1 (0.66) | PTGS1PTGS2 | |
| SCHEMBL5857924 | 0.90 | PTGS1 (0.64) | PTGS1PTGS2CA2 | |
| SCHEMBL5857642 | 0.89 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5858890 | 0.89 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5856792 | 0.89 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5856767 | 0.89 | PTGS1 (0.63) | PTGS1PTGS2 | |
| SCHEMBL5713124 | 0.89 | PDE5A (0.58) | PTGS1PTGS2 | |
| SCHEMBL6560048 | 0.86 | PTGS1 (0.60) | PTGS1PTGS2CA1CA2ACHE | |
| SCHEMBL5857443 | 0.86 | CA2 (0.64) | PTGS1PTGS2CA1CA2ACHE | |
| SCHEMBL5856805 | 0.86 | PTGS1 (0.74) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | claimed |
| US-RE38963-E1 | Pyrazoline derivatives, their preparation and application as medicaments | LABORATORIOS DEL DR. ESTEVE (ES) | 2006-01-31 | — | — | US | claimed |
| EP-1516621-A2 | Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-23 | — | — | EP | claimed |
| EP-1083171-B1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2004-04-28 | — | — | EP | claimed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | claimed |
| EP-1384477-A1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-28 | — | — | EP | claimed |
| US-6353117-B1 | ANTIINFLAMMATORY ACTIVITY AND DISEASES IN WHICH CYCLOOXYGENASE-2 PLAYS A PART, WITHOUT HAVING THE GASTRIC AND RENAL TOXICITY OF THE CLASSIC NONSTEROIDAL ANTIINFLAMMATORY AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-03-05 | — | — | US | claimed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | claimed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | disclosed |
| US-12208085-B2 | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals | ECUPHAR NV (BE) | 2025-01-28 | — | — | US | disclosed |
| US-20230381140-A1 | PYRAZOLINE-DERIVED COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED TO SURGERY IN MAMMALS | ECUPHAR NV (BE) | 2023-11-30 | — | — | US | disclosed |
| EP-4029502-A1 | PYRAZOLINE-DERIVED COMPOUND (ENFLICOXIB) FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED TO SURGERY IN MAMMALS | Ecuphar N.V. (BE) | 2022-07-20 | — | — | EP | disclosed |
| EP-4029502-A1 | PYRAZOLINE-DERIVED COMPOUND (ENFLICOXIB) FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED TO SURGERY IN MAMMALS | Ecuphar N.V. (BE) | 2022-07-20 | — | — | EP | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-02-19 | — | — | US | disclosed |
| EP-1384477-A1 | UTILIZATION OF PYRAZOLINE DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND/OR TREATMENT OF PROLIFERATIVE CELL DISEASES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-01-28 | — | — | EP | disclosed |
| WO-2004006931-A2 | PHARMACEUTICAL COMPOSTIONS COMPRISING AN ALLOSTERIC CARBOXYLIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
| US-6353117-B1 | ANTIINFLAMMATORY ACTIVITY AND DISEASES IN WHICH CYCLOOXYGENASE-2 PLAYS A PART, WITHOUT HAVING THE GASTRIC AND RENAL TOXICITY OF THE CLASSIC NONSTEROIDAL ANTIINFLAMMATORY AGENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-03-05 | — | — | US | disclosed |
| EP-1083171-A1 | PYRAZOLINE DERIVATIVES, THEIR PREPARATION AND APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381140-A1 | PYRAZOLINE-DERIVED COMPOUND FOR USE IN THE PREVENTION AND/OR TREATMENT OF PAIN AND INFLAMMATION ASSOCIATED TO SURGERY IN MAMMALS | IL1A, IL1B, P2RX7 | PTGS2 67/4885PTGS1 29/4885CA1 2761/4885 |
| US-12208085-B2 | Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals | IL1A, IL1B, P2RX7 | PTGS2 67/4885PTGS1 29/4885CA1 2761/4885 |
| US-20040034082-A1 | Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases | VHL, MET, PRMT1 | PTGS2 3894/4885PTGS1 1996/4885CA1 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.